articleTop 10% cited

Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

Clinical Cancer Research · 2005 · Vol. 11(18) · pp. 6713–6721

Eiji Suzuki✉(University of Pennsylvania)Veena Kapoor(University of Pennsylvania)Arminder S. Jassar(University of Pennsylvania)Larry R. Kaiser(University of Pennsylvania)Steven Μ. Albelda(University of Pennsylvania)

View via DOI Publisher page

Abstract

These results suggest that gemcitabine may be a practical strategy for the reduction of myeloid suppressor cells and should be evaluated in conjunction with a variety of immunotherapy approaches.

Immune Cell Function and Interaction Immune cells in cancer Immunotherapy and Immune ResponsesMyeloid-derived Suppressor CellCancer researchGemcitabineMyeloidCytotoxic T cellCD8Immune systemImmunotherapyBiologyImmunology

MeSH terms

GemcitabineAdenoviridaeAnalysis of VarianceAnimalsAntineoplastic AgentsB-LymphocytesCell LineDeoxycytidineFemaleFlow CytometryGenetic VectorsImmunotherapyKiller Cells, NaturalMice, Inbred BALB CMice, Inbred C57BL

Citations

1,047

FWCI

5.37

field-weighted impact

References

Percentile

97%

vs. same field & year

Citations per year

Cited by

Classification of current anticancer immunotherapies